Bcl10 是一種細胞凋零調節因子，基因座落在1p22，是一處抑癌基因。本研究以反轉錄脢聚合鏈反應、西方點墨法、免疫組織化學染色，篩撿Bcl10在各種癌細胞的表現率。

結果U87、星細胞瘤有Bcl10基因表現；神經膠質瘤、神經膠質母細胞瘤則沒有。西方點墨法發現肝癌、肺癌、乳癌、神經膠質母細胞瘤有 Bcl10和 NF-κB的蛋白質表現。免疫組織化學染色看到 神經膠質母細胞瘤 U373, U251； 口腔癌 CA922， SAS， 臨床病人VGH283； 肺癌 PC13， PC14； 肝癌 Huh7； 大腸癌 SW480； 子宮頸癌HeLa 都有 Bcl10 蛋白質反應。

Bcl10 只有選擇性在特定幾種癌細胞出現，特別例如淋巴癌。本研究顯示以前研究文獻沒有報告過的結果：Bcl10 在腦癌、口腔癌、及一些癌細胞扮演重要的角色。

Bcl10 is one of the apoptosis regulatory protein. It is located at 1p22,one site harbor tumor suppressor tumor gene. We screen Bcl10 expression in different tumor cell lines by reverse transcription-polymerase chain reaction(RT-PCR), western blot(WB) and immunohistochemistry(IHC).

The results showed Bcl10 genomic expression was found in U87, Astrocytoma and no expression in glioma , glioblastoma. There were cell lines with expressions in Bcl10 protein and NF-κB including hepatocellular carcinoma, glioblastoma, and breast cancer, but increased in lung cancer cell line. In immunohistochemistry,we found the Bcl10 protein has positive finding in glioma U373, U251; oral cancer CA922, SAS, clinical patient VGH283; Lung cancer PC14, PC13; Hepatoma Huh7; Colon cancer SW 480; Cervical cancer HeLa.

The Bcl10 gene, unlike other tumor suppressor genes such as p53, may be selectively targeted by different human tumors. In our study, Bcl10 play a role in brain tumor, oral cancer and some tumor cell line had not been reported before.

介紹 P7
實驗材料與方法 P19
結果 P22
討論 P23
參考文獻 P27
圖表
圖表1 P31
圖表2 P32
圖表3 P33
圖表4 P35
圖表5 P37
圖表6 P39
圖表7 P40
圖表8 P41
圖表9 P43
圖表10 P44
圖表11 P45
圖表12 P47
圖表13 P49
圖表14 P50
圖表15 P51

Albert, S. B. (2001). Control of oncogenesis and cancer therapy resistence by the transcription factor NF-κB. Journal of Clinical Investigation 107, 241-246.

Apostolou, S., Rienzo, A.D., Murthy, S.S., Jhanwar S.C., and Testa, J.R. (1999). Absence of Bcl10 mutations in human malignant mesothelioma. Cell 97, 684-686.

Beato, M. S., Aguilera, A. S., and Piris, M. A. (2003) Cell cycle deregulation in B-cell lymphoma. Blood 101, 1220-1235.

Bertin, J., Wang, L., Guo, Y., Jacobson, M. D., Poyet, J. L., Svinivascula, S. M., Merriam, S., DisStefano, P. S., and Alnemri, E. S. (2001). CARD 11 and CARD 14 are novel caspase recruitment domain (CARD)/ membrane-associated guanylate kinases (MAGUK) family members that interact with Bcl10 and activate NF-κB. The Journal of Biological Chemistry 276,11877-11882.

Bullinger, L., Schaffner, C., Mertens, D., Bentz, M., Lichter, Dohner, H., and Stilgenbauer, S. (2000). Bcl10 is not the gene inactivated by mutation in the 1p22 deletion region in mantle cell lymphoma. Leukemia 14, 1490-1492.

Cavalli, F., Isaacson, P. G., Gascoyne, R. D., and Zucca E. (2001) MALT lymphomas. Hematology 2001, 241-258.

Du, M. M., Peng, H., Liu, H., Hamoudi, T. C., Willis, T. G., Ye, H., Dogan, A., Wotherspoon, A. C., Dyer, M. J. S., and Isaacson, P. G. (2000). Bcl10 gene mutation in lymphoma. Blood 95, 3885-3990.

Duke, V., Kapoor, A. A., Gricks, C., Melo, J., and Foroni, L. (2000). Bcl10 deletions in haematological malignancies: a cloning artefact? British Journal of Haematology 111, 1106-1108.

Dyer, M. J. S. (1999). Bcl10 mutations in malignancy. British Journal of Cancer 80,1491.

Dyer, M. J. S., Price, H. P., Jadayel, D. M., et al. (1999). In response to Fakruddin et al and Apostolou et al. Cell 97, 686.

Fakruddin, J.M., Chaganti, RSK, and Murty VVVS. (1999). Lack of Bcl10 mutations in germ cell tumors and B cell lymphomas. Cell 97, 683-688.

Gaide, O., Martinon, F., Micheau, O., Bonnet, D., Thome, M., and Tschopp, J., (2001) Carma1, a CARD-containing binding partner of Bcl10, induced Bcl10 phosphorylation and NF-κB activation. FEBS Letters 496, 121-127.

Gill, S., Broni, J., Jefferies, S., Osin, P., Kovacs, G., Maitland, N. J., Eeles, R., Edwards, S. M., Dyer, M. J. S., Willis, T. G., and Cooper, C. S. (1999). Bcl10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinomas. British Journal of Cancer 80, 1565-1568.

Grimwade, D., Du, M. M., Langabeer, S., Rogers, J., and Solomon, E. (2000) Screening for mutations of Bcl10 in leukemia. British Journal of Haematology 109, 611-615.

Haye, L. B., and Martin, S. M. (2002). CARD games in apoptosis and immunity. EMBO reports 3, 616-621.

Lambers, A. R., Gumbs, C., Ali, S., Ali, S., Matks, J. R., Iglehart, J. D.,Berchuck, A., and Futreal, P. A. (1999). Bcl10 is not a target for frequent mutation in human carcinomas. British Journal of Cancer 80, 1575-1576.

Lee, S. H., Shin, M. S., Kim, H. S., Park, W. S., Kim, S. Y., Lee, H. K., Park, W. S., Kim, S. Y. Lee, H. K., Park, J. Y. Oh, R. R., Jang, J. J., Park, M. K., Han, J. Y., Kang, C. S., Lee, J. Y., and Yoo, N. J. (1999). Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphoma. Cancer Reserch 59, 5674-5677.

Lodish, H., Berk, A., Zipursky, S. L., Mastudaria, P., Baltimore, D., and Darnell, J. E., (1999). Molecular Cell Biology 4th, 1054-1084.

Lucas, P. C., Mcallister-Lucas, L. M., and Nunez, G. (2004). NF-κB signaling in lymphocytes: a new cast of characters. Journal of Cell Science 117, 31-39.
Lucas, P. C., Yonezumi, M., Inohara, M., Mcallister, L. M., Abazeed, M. E., Yamaoka, S., Seto, M., and Nunez, G. (2001). Bcl10 and MALT1, independent targets of chromosome translocation in MALT lymphoma, cooperative in a novel NF-κB signaling pathway. The Journal of Biological Chemistry 276, 19012-19019.

Luminaris, S, Intini, D., Baldini, L., Berti, E.,Bertoni, F., Zucca, E.,Cro, L., Maiolo, A. T., Cavalli, F., and Neri, A. (2000). Bcl10 gene mutations rarely occur in lymphoid malignancies. Leukemia 14, 905-908.

Park, Y. K., Chi, S. G., and Unni, K. K. (2001). Absence of Bcl10 gene mutations in Ewing’s sarcoma. Oncology Reports 8, 1333-1335.

Park, Y. K., Park, H. R., Kim, Y. W., Chi, S. G., and Unni, K. K. (2002). Lack of Bcl10 mutations in malignant cartilaginous tumors. International Journal of Molecular Medicine 9, 217-219.

Scharshmid, E., Wegener, E., Heissmeyer, V., Rao, A., and Krappmann, D. (2004). Degradation of Bcl10 induced by T- cell activation negatively regulates NF-κB signaling. Molecular and Cellular Biology 24, 3860-3873.

Schmitz, M. L., Bacher, S., and Dienz O., (2003). NF-κB activation pathways induced by T cell costimulation. The FASEB Journal 17, 2187-2193

Schothorst, E. M., Mohkamsing, S., van Gurp R.J.H.L.M., Oosterhuis J. W., van der Saag P. T, and Looijenga, LHJ. (1999). Lack of Bcl10 mutations in testicular germ cell tumors and derived cell lines. British Journal of Cancer 80, 1571-1574.

Shen, L. Liang, A. C. T, Lu, L. Au, W. Y. Wong, K. Y., Tin, P. C., Chan, K.W., Ko, K. H., Chen, Y.W., Beh, S. L., Shimizu, N. Tsuchiyama, J., Tang, J. C. O., Kwong, Y. L., Liang, R. H. S., and Srivastava, G. (2003) Aberrant Bcl10 nuclear expression in nasal NK / T-cell lymphoma. Blood 102, 1553-1554.

Stone, J.G., Rowan, A.J., Tomlison, I. P. M, and Houlston, R.S. (1999). Mutations in Bcl10 are very rare in colorectal cancer. British Journal of Cancer 80, 1569-1570.

Takahashi, H., Hosokawa, Y., Suzuki, R., Morishima, Y., Nakamura, S., and Seto, M. (1999). Infrequent Bcl10 mutations in B-cell non-Hodgkin’s lymphomas. Japan Journal of Cancer Reserch. 90, 1316-1320.

Takahashi, H., Maeda, Y., Seto, M., and Hosokawa, Y. (2000). Nucleotide insertions and deletions within the homopoltmeric runs of adenines and thymidines of Bcl10 cDNAs in normal peripheral blood leukocytes. Blood 95, 2728-2729.

Thome, M. and Tschopp, J. (2003). TCR-induced NF-κB activation: a crucial role for Carma1, Bcl10 and MALT1. TRENDS in Immunology 24, 419-423.

Wang, D., Matsumoto, R., You, Y., Che, T. Lin, X. Y., Gaffen, S. L., and Lin, X. (2004) CD3/CD28 costimulation-induced NF-κB activation is mediated by recruitment of protein kinase C-θ, Bcl10, and IκB kinase B to the immunological synapse through CARMA1. Molecular and Cellular Biology 24, 164-171.

Willis, T. G., Jadayel, D. M., Ming-Qing, D., Peng, H.,Perry, A. R., Abdul-Raul, M., Price, H., Karran, L., Majekodunmi, O., Wlodarska, I. Pan, L., Crook, T., Hamoudi, R., Isaacson, P. G., and Dyer, M. J. S.(1999). Bcl10 is involved in t(1;14)(p22;q32) of MALT B-cell lymphoma and mutated in multiple tumor types. Cell 96, 35-45.

Ye, H., Dogan, A., Karren, L., Willis, T. G., Chen, L.,Wlodarska, I., Dyer, M. J. S., Issaacson, P. G., and Du, M. M. (2000) Bcl10 expression in normal and neoplastic lymphoid tissue. Amierican Journal of Pathology 157, 1147-1154.
Zhang, Q., Siebert, R., Yan, M., Hinzmann, B., Cui, X., Xue, L., Rakestraw, K. M., Naeve, C. W., Beckmann, G., Weisenburger, D. D., Sanger, W. G., Nowotny, H., Vesely, M., Callet- Bauchu, E., Salles, G., Dixit,V. M., Rosenthal, A., Schlegelberger, B., Morris, S. M. (1999). Inactivating mutations and overexpression of Bcl10, caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 22, 63-68.

Zhou, H., Wertz, I., O’Rourke, K., Ultsch, M., Seschagiri, S., Eby, M., Xiae, W.,and Dixit, V. M. (2004). Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 427, 167-171.